Watson Aslera
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Approval of the lupus treatment prasterone may be delayed, Watson reports in a May 7 conference call. FDA is expected to reach a decision on approvability of the product by the June 26 user fee goal. The potential delay in approval follows an April 19 review by FDA's Arthritis Advisory Committee. The group did not vote on approval, but members expressed concern about Aslera's failure to reach initially defined primary endpoints in the pivotal trials
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.